Brokerages Set Illumina, Inc. (NASDAQ:ILMN) Target Price at $125.11

Illumina, Inc. (NASDAQ:ILMN) has been assigned an average rating of “Hold” from the twenty brokerages that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $125.11.

Several research firms have commented on ILMN. Canaccord Genuity Group boosted their target price on Illumina from $87.00 to $99.00 and gave the stock a “hold” rating in a report on Wednesday, June 11th. Morgan Stanley reduced their price objective on Illumina from $136.00 to $100.00 and set an “equal weight” rating for the company in a research report on Monday, May 12th. Guggenheim reduced their price objective on Illumina from $122.00 to $114.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Barclays restated an “underweight” rating and issued a $85.00 price target (up previously from $77.00) on shares of Illumina in a research report on Tuesday, June 24th. Finally, JPMorgan Chase & Co. dropped their price objective on Illumina from $120.00 to $85.00 and set a “neutral” rating for the company in a research note on Friday, May 9th.

Insider Buying and Selling

In related news, CFO Ankur Dhingra purchased 6,100 shares of the business’s stock in a transaction dated Monday, May 12th. The shares were acquired at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the acquisition, the chief financial officer owned 24,906 shares of the company’s stock, valued at $2,022,616.26. The trade was a 32.44% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. ORG Wealth Partners LLC boosted its position in shares of Illumina by 52.5% in the 2nd quarter. ORG Wealth Partners LLC now owns 4,234 shares of the life sciences company’s stock worth $416,000 after purchasing an additional 1,458 shares in the last quarter. Signaturefd LLC increased its stake in shares of Illumina by 194.9% in the 2nd quarter. Signaturefd LLC now owns 4,742 shares of the life sciences company’s stock valued at $452,000 after purchasing an additional 3,134 shares in the last quarter. A. D. Beadell Investment Counsel Inc. purchased a new position in shares of Illumina in the 2nd quarter valued at about $215,000. Harrell Investment Partners LLC purchased a new position in shares of Illumina in the 2nd quarter valued at about $374,000. Finally, Ballentine Partners LLC increased its stake in Illumina by 311.3% during the 2nd quarter. Ballentine Partners LLC now owns 10,707 shares of the life sciences company’s stock worth $1,022,000 after buying an additional 8,104 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Price Performance

ILMN opened at $96.96 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.48 and a current ratio of 1.86. Illumina has a 52-week low of $68.70 and a 52-week high of $156.66. The stock has a market capitalization of $15.35 billion, a PE ratio of -15.97, a price-to-earnings-growth ratio of 1.91 and a beta of 1.36. The stock’s 50 day moving average price is $88.45 and its 200-day moving average price is $95.70.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.01. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same period in the previous year, the company posted $0.98 earnings per share. The firm’s revenue was down 1.4% on a year-over-year basis. On average, equities research analysts predict that Illumina will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.